Innova Captab

Innova Captab Revenue per Share

The Revenue per Share of Innova Captab (INNOVACAP.NS) as of Nov 22, 2026 is 280.28 INR. In the previous year, Revenue per Share was 217.33 INR — a change of 28.97% (higher).

Revenue per Share

280.28INR

YoY

28.97%

Last updated:

Revenue per Share of Innova Captab is 2026 280.28 INR. Revenue per Share of Innova Captab was 2025 217.33 INR. It decreases by 28.97% higher compared to the previous year.

The Innova Captab Revenue per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
Date
Revenue per Share
Jan 1, 2021
71.57 INR
Jan 1, 2022
139.76 INR
Jan 1, 2023
161.86 INR
Jan 1, 2024
187.97 INR
Jan 1, 2025
217.33 INR
Jan 1, 2026
280.28 INR
Jan 1, 2027 (e)
360.42 INR
Jan 1, 2028 (e)
439.99 INR
The Innova Captab Revenue per Share history
YEARRevenue per ShareYoY
est439.99INR+22.08%
est360.42INR+28.59%
280.28INR+28.97%
217.33INR+15.62%
187.97INR+16.14%
161.86INR+15.81%
139.76INR+95.27%
71.57INR+9.71%
65.24INR-24.36%
86.25INR+108.99%
41.27INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Innova Captab Stock analysis

What does Innova Captab do? Innova Captab Ltd generates revenue through its CDMO business, which offers research, product development, and manufacturing services to clients in the pharmaceutical sector. The company also earns from its domestic branded generics business, developing, manufacturing, and distributing generic formulation products under its own brand names across India via online and offline channels. Additionally, Innova Captab sells its generic drug products through various e-commerce pharmacy sites. The company's diversified portfolio includes tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals. Its international branded generic product business focuses on exporting branded generic products globally. Innova Captab's primary customers are pharmaceutical companies seeking CDMO services, Indian consumers purchasing generic medicines through retail and online pharmacies, and international buyers of branded generic products. The domestic market segment is served through branded generics sold under the company's own brand names, while the international segment targets global markets for branded generic drug exports. The company's value chain spans research and development, manufacturing, drug distribution, marketing, and exports, ensuring comprehensive coverage across the pharmaceutical industry. The company's product segments include CDMO services, domestic branded generics, and international branded generics. CDMO services are provided to pharmaceutical firms requiring outsourced research and manufacturing. Domestic branded generics are marketed in India under the company's brand names through both online and offline channels. International branded generics are exported to global markets, leveraging the company's manufacturing capabilities and product portfolio. Innova Captab's business model integrates all stages of the pharmaceutical value chain, from R&D to exports, to deliver a full-service solution for its clients and customers. Innova Captab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Innova Captab stock

Revenue per Share of Innova Captab is 280.28 INR in 2026.

Revenue per Share of Innova Captab changed from 217.33 INR to 280.28 INR, representing a 28.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Revenue per Share Innova Captab since 2006 – with annual values, charts, and detailed analysis.

Revenue per Share divides total revenue by shares outstanding, showing how much revenue each share represents.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Innova Captab

All Key Metrics — Innova Captab